MMP9 and osteosarcoma: found that after treatment with sorafenib in osteosarcoma cells and animal models, NF-κB activity can be significantly inhibited to reduce the expression of anti-apoptotic protein and transfer-related protein (MMP-2, MMP-9) encoded by NF-κB target genes and reduce cell invasion of osteosarcoma (180).